Abiopharma

🔍 Manieu Alexandre Weinstein (Director)

Company: Pluri Inc. (PLUR)

Report Date: 2025-12-30

Detailed Transactions and Holdings:

• Acquired 625,000 shares of Common Stock at $2.0 per share (Direct)
  Date: 2025-12-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 625,000.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-30 | Code: H | nature_of_ownership: Shares indirectly held through Plantae Bioscience Ltd. | shares_owned_after: 452,702.00 | Footnotes: F4
• Acquired 625,000 shares of Warrants at $4.25 per share (Derivative)
  Date: 2025-12-08 | Code: A | Expires: 2026-06-30 | Exercise: 2025-12-08 | equity_swap_involved: 0 | shares_owned_after: 625,000.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: On December 8, 2025, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with Chutzpah Holdings LP, a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company ("Mr. Weinstein"), relating to a private placement offering (the "Offering") of: (i) 625,000 common shares, par value $0.00001 per share (the "Common Shares") of the Company, and (ii) warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and Common Warrant is $4.00.
• F2: (Continuation of Footnote 1) The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties.
• F3: This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
• F4: Mr. Weinstein indirectly owns approximately 78.32% of PBL and may be deemed to beneficially own securities owned by PBL. Neither the filing of this statement nor anything herein shall be deemed an admission that Mr. Weinstein is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities owned by PBL. Mr. Weinstein disclaims beneficial ownership of such securities covered by this statement, except to the extent of his pecuniary interest in such securities. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.
• REMARKS: Exhibit Index: Exhibit 1 - Joint Filer Information. Exhibit 2 - Joint Filing Agreement dated January 5, 2026. Each reporting person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities covered by this statement. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.